Drug Trial Radar · NCT04794699
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
169
Actual
Start
Apr 14, 2021
Primary completion
Jan 7, 2027
Study completion Feb 4, 2027
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Conditions
- Solid Tumor
Interventions
IDE397Drug
IDE397 dosed orally
Sacituzumab govitecanDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting Toxicities (DLTs) of IDE397Time frame: 21 days following the first dose of IDE397
- Dose-limiting Toxicities (DLTs) of IDE397 in combination with sacituzumab govitecanTime frame: 21 - 28 days following the first dose of IDE397
- Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397Time frame: Approximately 2 years
- Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 in combination with sacituzumab govitecanTime frame: Approximately 2 years
- To evaluate preliminary anti-tumor activity of IDE397 as monotherapy and in combination with sacituzumab govitecan-hziy in expansion armsTime frame: Approximately 2 years
Locations
37 sites in 7 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
Rockefeller Cancer Institute
Little Rock, Arkansas
City of Hope
Duarte, California
Orlando Health Cancer Institute
Orlando, Florida
Indiana University Health Hospital
Indianapolis, Indiana
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York
Weill Cornell Medical College
New York, New York
Stephenson Cancer Center
Oklahoma City, Oklahoma
LifeSpan - Brown University
Providence, Rhode Island
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson
Houston, Texas
Next Oncology
San Antonio, Texas
Swedish Cancer Institute
Seattle, Washington
The Kinghorn Cancer Centre, St Vincent's Health Network Sydney
Darlinghurst, New South Wales, Australia
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia
Centre Georges Francois LeClerc
Dijon, France
Centre Eugène Marquis
Rennes, France
Gustave Roussy
Villejuif, France
Institut Bergonie
Bordeaux, Bordeaux Cedex, France
Institut Claudius Regaud - IUCT-Oncopole
Toulouse, Cedex 9, France
Hôpital Timone
Marseille, Marseille, France
Universitaetsklinikum Hamburg-Eppendorf (UKE)
Hamburg, Germany
Sevrance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
CHA University - Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Hospital Universitario 12 de Octubre (H12O)
Madrid, Spain
START Madrid-HM - Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, Spain
NEXT Madrid, Universitary Hospital QuironSAlud
Madrid, Spain
Instituto Valenciano de Oncología (IVO)
Valencia, Spain
National Cheng Kung University Hospital
Tainan, Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.